Patents by Inventor Christian Klein

Christian Klein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF CANCER USING A HLA-A2/WT1 X CD3 BISPECIFIC ANTIBODY AND LENALIDOMIDE
    Publication number: 20220275093
    Abstract: The present invention relates to the treatment of cancer, in particular to the treatment of cancer using a HLA-A2/WT1×CD3 bispecific antibody and lenalidomide.
    Type: Application
    Filed: May 5, 2022
    Publication date: September 1, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Christian AUGSBERGER, Christian KLEIN, Sabine Marion SUBKLEWE
  • Eye gaze control of magnification user interface
    Patent number: 11430414
    Abstract: Techniques for providing adaptive assistive technology for assisting users with visual impairment can be used on a computing device. These techniques include displaying content to a user, capturing a series of images or video of the user using a camera, analyzing the series of images or video to determine whether the user is exhibiting behavior or characteristics indicative of visual impairment, and rendering a magnification user interface on the display configured to magnify at least a portion of the content of the display based on a determination that the user is exhibiting behavior or characteristics indicative of visual impairment. The magnification user interface may be controlled based on head and/or eye movements of the user of the computing device.
    Type: Grant
    Filed: October 17, 2019
    Date of Patent: August 30, 2022
    Assignee: Microsoft Technology Licensing, LLC
    Inventors: Jason A. Grieves, Eric N. Badger, Grant M. Wynn, Paul J. Olczak, Christian Klein
  • COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR
    Publication number: 20220265642
    Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
    Type: Application
    Filed: March 30, 2022
    Publication date: August 25, 2022
    Applicants: GENENTECH, INC., HOFFMANN-LA ROCHE INC., ABBVIE INC.
    Inventors: Deepak Sampath, Christian Klein, Wayne John Fairbrother, Sari L. Heitner Enschede, Rod A. Humerickhouse, Andrew W. Roberts, John F. Seymour
  • ANTIGEN BINDING MOLECULES COMPRISING A TRIMERIC TNF FAMILY LIGAND
    Publication number: 20220267395
    Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen, (b) a polypeptide comprising three ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by peptide linkers and (c) a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: November 18, 2021
    Publication date: August 25, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Maria Amann, Peter Bruenker, Christina Claus, Claudia Ferrara Koller, Sandra Grau-Richards, Christian Klein, Viktor Levitski, Ekkehard Moessner, Pablo Umana
  • FUSION OF AN ANTIBODY BINDING CEA AND 4-1BBL
    Publication number: 20220267464
    Abstract: The invention relates to new humanized CEA antibodies and to CEA targeting 4-1BBL trimer-containing antigen binding molecules comprising these CEA antibodies as well as their use in the treatment of cancer.
    Type: Application
    Filed: December 17, 2021
    Publication date: August 25, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Claudia Ferrara Koller, Thomas Hofer, Christian Klein, Ekkehard Moessner, Christina Claus, Ralf Hosse, Bianca Scherer, Pablo Umana
  • ANTIBODIES WHICH BIND TO CANCER CELLS AND TARGET RADIONUCLIDES TO SAID CELLS
    Publication number: 20220267463
    Abstract: The present invention relates to antibodies which bind to antigens on target cells and which target radionuclides to said cells, and to methods of using the same.
    Type: Application
    Filed: July 10, 2020
    Publication date: August 25, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Pablo UMANA, Sabine IMHOF-JUNG, Alexander HAAS, Christian KLEIN, Sofia FROST, Felix BORMANN, Guy GEORGES, Sebastian FENN, Florian LIPSMEIER, Daniela MATSCHEKO, Joerg MOELLEKEN, Barbara WEISER
  • ANTIGEN BINDING MOLECULES COMPRISING A TNF FAMILY LIGAND TRIMER
    Publication number: 20220259327
    Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof.
    Type: Application
    Filed: January 21, 2022
    Publication date: August 18, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Maria Amann, Peter Bruenker, Christina Claus, Claudia Ferrara Koller, Sandra Grau-Richards, Christian Klein, Viktor Levitski, Ekkehard Moessner, Joerg Thomas Regula, Pablo Umana
  • ANTIBODIES BINDING TO GPRC5D
    Publication number: 20220259318
    Abstract: The present invention generally relates to antibodies that bind to GPRC5D, including bispecific antigen binding molecules e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Application
    Filed: January 28, 2022
    Publication date: August 18, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: ALEXANDER BUJOTZEK, TONY CHRISTOPEIT, TANJA FAUTI, GEORG FERTIG, HÉLÈNE CÉCILE HAEGEL, CHRISTIAN KLEIN, THOMAS KRAFT, STEFAN LORENZ, MAUD LÉA MAYOUX, ANNELIESE SCHNEIDER
  • ANTIGEN BINDING MOLECULES COMPRISING A TNF FAMILY LIGAND TRIMER
    Publication number: 20220259326
    Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof.
    Type: Application
    Filed: January 21, 2022
    Publication date: August 18, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Maria Amann, Peter Bruenker, Christina Claus, Claudia Ferrara Koller, Sandra Grau-Richards, Christian Klein, Viktor Levitski, Ekkehard Moessner, Joerg Thomas Regula, Pablo Umana
  • BISPECIFIC ANTIBODIES SPECIFIC FOR PD1 AND TIM3
    Publication number: 20220259314
    Abstract: The invention relates to bispecific antibodies comprising a first antigen-binding site that specifically binds to PD1 and a second antigen-binding site that specifically binds to TIM3, in particular to bispecific antibodies, wherein the bispecific antibody binds to 5 TIM3 with a lower binding affinity when compared to the binding to PD1. The invention further relates to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: September 3, 2021
    Publication date: August 18, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: LAURA CODARRI-DEAK, GEORG FERTIG, JENS FISCHER, CHRISTIAN KLEIN, VIKTOR LEVITSKI, VALERIA LIFKE, MARIO PERRO, JOERG THOMAS REGULA, TILMAN SCHLOTHAUER, STEFAN SEEBER, PABLO UMANA, ILDIKO WUENSCHE, ADRIAN ZWICK
  • Immunoconjugates
    Patent number: 11413331
    Abstract: The present invention generally relates to immunoconjugates, particularly immunoconjugates comprising a mutant interleukin-2 polypeptide and an antibody that binds to PD-1. In addition, the invention relates to polynucleotide molecules encoding the immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: August 16, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Laura Codarri Deak, Christian Klein, Laura Lauener, Valeria G. Nicolini, Stefan Seeber, Pablo Umana, Inja Waldhauer
  • Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor
    Patent number: 11413282
    Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective BCL-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: August 16, 2022
    Assignees: GENENTECH, INC., HOFFMANN-LA ROCHE INC., ABBVIE INC.
    Inventors: Deepak Sampath, Christian Klein, Wayne John Fairbrother
  • NOVEL IMMUNOCONJUGATES
    Publication number: 20220242971
    Abstract: The present invention generally relates to antigen-specific immunoconjugates for selectively delivering effector moieties that influence cellular activity. More specifically, the invention provides novel immunoconjugates comprising a first antigen binding moiety, an Fc domain and a single effector moiety. In addition, the present invention relates to polynucleotides encoding such immunoconjugates, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the immunoconjugates of the invention, and to methods of using these immunoconjugates in the treatment of disease.
    Type: Application
    Filed: September 27, 2021
    Publication date: August 4, 2022
    Applicant: Roche Glycart AG
    Inventors: Oliver AST, Peter BRUENKER, Thomas U. HOFER, Ralf HOSSE, Christian KLEIN, Ekkehard MOESSNER, Pablo UMANA
  • BISPECIFIC ANTIGEN BINDING MOLECULES COMPRISING ANTI-FAP CLONE 212
    Publication number: 20220227878
    Abstract: The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP) comprising FAP clone 212 or variants thereof, and (b) at least one antigen binding domain capable of specific binding to CD40, and to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: December 21, 2021
    Publication date: July 21, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Peter BRUENKER, Harald DUERR, Christian KLEIN, Pablo UMANA, Alexander BUJOTZEK, Joerg ZIELONKA, Christine TRUMPFHELLER, Moritz RAPP, Marine LE CLECH
  • T CELL ACTIVATING BISPECIFIC ANTIGEN BINDING MOLECULES
    Publication number: 20220220224
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target 511cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: January 20, 2022
    Publication date: July 14, 2022
    Inventors: Marina BACAC, Peter BRUENKER, Anne FREIMOSER-GRUNDSCHOBER, Ralf HOSSE, Christian KLEIN, Ekkehard MOESSNER, Pablo UMANA, Tina WEINZIERL
  • COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR
    Publication number: 20220211696
    Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
    Type: Application
    Filed: August 5, 2021
    Publication date: July 7, 2022
    Applicants: GENENTECH, INC., HOFFMANN-LA ROCHE INC., ABBVIE INC.
    Inventors: Deepak Sampath, Christian Klein, Wayne John Fairbrother, Sari L. Heitner Enschede, Rod A. Humerickhouse, Andrew W. Roberts, John F. Seymour
  • T CELL ACTIVATING BISPECIFIC ANTIGEN BINDING MOLECULES
    Publication number: 20220213224
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells comprising a common light chain. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: September 9, 2021
    Publication date: July 7, 2022
    Inventors: Christian KLEIN, Ekkehard MOESSNER, Ralf HOSSE, Peter BRUENKER, Pablo UMANA, Christiane NEUMANN
  • Interleukin-2 fusion proteins and uses thereof
    Patent number: 11365232
    Abstract: The present invention generally relates to fusion proteins of immunoglobulins and interleukin-2 (IL-2). In addition, the present invention relates to polynucleotides encoding such fusion proteins, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the fusion proteins of the invention, and to methods of using them in the treatment of disease.
    Type: Grant
    Filed: February 5, 2020
    Date of Patent: June 21, 2022
    Assignee: Roche Glycart AG
    Inventors: Ralf Hosse, Christian Klein, Ekkehard Moessner, Laurence Bernard Peterson, Pablo Umana, Linda Wicker
  • PREVENTION OR MITIGATION OF T-CELL ENGAGING AGENT-RELATED ADVERSE EFFECTS
    Publication number: 20220168418
    Abstract: The present invention relates to the prevention or mitigation of adverse effects related to T cell engaging agents, such as cytokine release syndrome. Specifically, the invention relates to the prevention or mitigation of such side effects using an inhibitor of JAK and/or mTOR.
    Type: Application
    Filed: November 9, 2021
    Publication date: June 2, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Hélène Cécile HAEGEL, Christian KLEIN, Gabrielle LECLERCQ, Alberto TOSO, Tina ZIMMERMANN
  • BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
    Publication number: 20220169748
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: February 11, 2022
    Publication date: June 2, 2022
    Inventors: Christian KLEIN, Marina BACAC, Anne FREIMOSER-GRUNDSCHOBER, Sylvia HERTER, Joaquin ARRIBAS, Rocio VICARIO